PDF(Sci-hub)
Abstract：
BACKGROUND: Among male sexual dysfunctions, erectile dysfunction and early ejaculation have the highest prevalence rates. Here, we tested the influence of lisdexamfetamine dimesylate (Vyas®) on early ejaculation. To this end, we performed a double-blind randomized clinical trial among males with early ejaculation.
METHODS: A total of 46 males with early ejaculation (mean age: 35.23 years) and in stable marital relationships with regular weekly penile-vaginal intercourse were randomly assigned either to the lisdexamfetamine dimesylate condition (30 mg) or to the placebo condition. Compounds were taken about six hours before intended penile-vaginal intercourse. At baseline and four weeks later at the end of the study, participants completed a series of self-rating questionnaires covering early ejaculation. Female partners also rated participants\' early ejaculation profile.
RESULTS: Compared to the placebo condition, dimensions of early ejaculation improved over time in the lisdexamfetamine condition, though improvements were also observed in the placebo condition.
CONCLUSIONS: Among male adults in stable marital relationships with regular weekly penile-vaginal intercourse, lisdexamfetamine dimesylate improved dimensions of early ejaculation. Given that improvements were also observed in the placebo condition, psychological factors such as increased attention to early ejaculation and favorable expectations of the compound should be considered.
METHODS: A total of 46 males with early ejaculation (mean age: 35.23 years) and in stable marital relationships with regular weekly penile-vaginal intercourse were randomly assigned either to the lisdexamfetamine dimesylate condition (30 mg) or to the placebo condition. Compounds were taken about six hours before intended penile-vaginal intercourse. At baseline and four weeks later at the end of the study, participants completed a series of self-rating questionnaires covering early ejaculation. Female partners also rated participants\' early ejaculation profile.
RESULTS: Compared to the placebo condition, dimensions of early ejaculation improved over time in the lisdexamfetamine condition, though improvements were also observed in the placebo condition.
CONCLUSIONS: Among male adults in stable marital relationships with regular weekly penile-vaginal intercourse, lisdexamfetamine dimesylate improved dimensions of early ejaculation. Given that improvements were also observed in the placebo condition, psychological factors such as increased attention to early ejaculation and favorable expectations of the compound should be considered.
摘要：
背景：在男性性功能障碍中，勃起功能障碍和早期射精的患病率最高。这里,我们测试了二甲磺酸盐(Vyas®)对早期射精的影响.为此,我们在男性早泄患者中进行了一项双盲随机临床试验.
方法：共有46名男性射精早（平均年龄：35.23岁），婚姻关系稳定，每周有规律的阴茎-阴道性交，被随机分配到lisdexamfetaminedimesylate状态（30mg）或安慰剂状态。在预期的阴茎-阴道性交之前约6小时服用化合物。在基线和四周后研究结束时，参与者完成了一系列涵盖早期射精的自评问卷.女性伴侣还对参与者的早期射精情况进行了评分。
结果：与安慰剂条件相比，在lisdexamfetamine条件下，早期射精的尺寸随着时间的推移而改善，尽管在安慰剂条件下也观察到改善。
结论：在具有稳定婚姻关系且每周有规律的阴茎-阴道性交的男性成年人中，lisdexamfetaminedimesylate改善早期射精的尺寸。鉴于在安慰剂条件下也观察到改善，应考虑心理因素，例如对早期射精的关注和对化合物的良好期望。
方法：共有46名男性射精早（平均年龄：35.23岁），婚姻关系稳定，每周有规律的阴茎-阴道性交，被随机分配到lisdexamfetaminedimesylate状态（30mg）或安慰剂状态。在预期的阴茎-阴道性交之前约6小时服用化合物。在基线和四周后研究结束时，参与者完成了一系列涵盖早期射精的自评问卷.女性伴侣还对参与者的早期射精情况进行了评分。
结果：与安慰剂条件相比，在lisdexamfetamine条件下，早期射精的尺寸随着时间的推移而改善，尽管在安慰剂条件下也观察到改善。
结论：在具有稳定婚姻关系且每周有规律的阴茎-阴道性交的男性成年人中，lisdexamfetaminedimesylate改善早期射精的尺寸。鉴于在安慰剂条件下也观察到改善，应考虑心理因素，例如对早期射精的关注和对化合物的良好期望。
